GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QHSLab Inc (OTCPK:USAQ) » Definitions » Debt-to-EBITDA

QHSLab (QHSLab) Debt-to-EBITDA : -37.13 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is QHSLab Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

QHSLab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.78 Mil. QHSLab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. QHSLab's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.05 Mil. QHSLab's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -37.13.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for QHSLab's Debt-to-EBITDA or its related term are showing as below:

USAQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -19.58   Med: -3.86   Max: -2.13
Current: -19.58

During the past 13 years, the highest Debt-to-EBITDA Ratio of QHSLab was -2.13. The lowest was -19.58. And the median was -3.86.

USAQ's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs USAQ: -19.58

QHSLab Debt-to-EBITDA Historical Data

The historical data trend for QHSLab's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QHSLab Debt-to-EBITDA Chart

QHSLab Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.22 -2.13 -2.66 -3.86 -19.58

QHSLab Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.85 -4.85 215.13 138.25 -37.13

Competitive Comparison of QHSLab's Debt-to-EBITDA

For the Medical Devices subindustry, QHSLab's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QHSLab's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, QHSLab's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where QHSLab's Debt-to-EBITDA falls into.



QHSLab Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

QHSLab's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.782 + 0) / -0.091
=-19.58

QHSLab's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.782 + 0) / -0.048
=-37.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


QHSLab  (OTCPK:USAQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


QHSLab Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of QHSLab's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


QHSLab (QHSLab) Business Description

Traded in Other Exchanges
N/A
Address
901 Northpoint Parkway, Suite 302, West Palm Beach, FL, USA, 33407
QHSLab Inc is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. It is a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCPs) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.
Executives
Troy James Grogan director, 10 percent owner, officer: CEO/Director 5480 N OCEAN DR B1D, SINGER ISLAND FL 33404
Richard J Rubin director, 10 percent owner, officer: CEO & Chairman 90 JOHN STREET, SUITE 626, NEW YORK NY 10038

QHSLab (QHSLab) Headlines

From GuruFocus

QHSLab. Issues Update and Investor Presentation May 2022

By GuruFocusNews GuruFocusNews 05-19-2022